Three biotechs hunt $336M-plus in a new round of IPOs — while Dermavant pulls back
Raise money when you can, not when you must — the common refrain rang loud in two IPO filings late Friday as ADC Therapeutics and Frequency …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
